Takeda Secures FDA Approval of MIMRYLO for Polycythemia Vera Treatment

Takeda (TSE:4502/NYSE:TAK) recently announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA) for MIMRYLO (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, […]